Ivonescimab continues to demonstrate strong clinical and commercial momentum, with positive phase III data, consistent OS benefit across regions, and a robust global development pipeline. Financially, the company maintains a strong cash position and is preparing for a potential U.S. launch pending FDA approval in November 2026.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.